BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20689331)

  • 1. Erythropoietin protects podocytes from damage by advanced glycation end-products.
    Ruester C; Franke S; Bondeva T; Wolf G
    Nephron Exp Nephrol; 2011; 117(1):e21-30. PubMed ID: 20689331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
    Loeffler I; Rüster C; Franke S; Liebisch M; Wolf G
    Am J Physiol Renal Physiol; 2013 Sep; 305(6):F911-8. PubMed ID: 23825071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
    Rüster C; Bondeva T; Franke S; Förster M; Wolf G
    Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity.
    Bondeva T; Wolf G
    Am J Nephrol; 2009; 30(4):336-45. PubMed ID: 19590177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner.
    Bondeva T; Wojciech S; Wolf G
    Am J Physiol Renal Physiol; 2011 Oct; 301(4):F852-70. PubMed ID: 21734098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end-products suppress neuropilin-1 expression in podocytes.
    Bondeva T; Rüster C; Franke S; Hammerschmid E; Klagsbrun M; Cohen CD; Wolf G
    Kidney Int; 2009 Mar; 75(6):605-16. PubMed ID: 19037249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression.
    Liebisch M; Bondeva T; Franke S; Daniel C; Amann K; Wolf G
    Kidney Int; 2014 Jul; 86(1):103-17. PubMed ID: 24476693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone-related protein induces hypertrophy in podocytes via TGF-beta(1) and p27(Kip1): implications for diabetic nephropathy.
    Romero M; Ortega A; Izquierdo A; López-Luna P; Bosch RJ
    Nephrol Dial Transplant; 2010 Aug; 25(8):2447-57. PubMed ID: 20200004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezrin contributes to impaired podocyte migration and adhesion caused by advanced glycation end products.
    McRobert EA; Bach LA
    Nephrology (Carlton); 2016 Jan; 21(1):13-20. PubMed ID: 26032400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin prevents diabetes-induced podocyte damage.
    Schiffer M; Park JK; Tossidou I; Bartels J; Shushakova N; Menne J; Fliser D
    Kidney Blood Press Res; 2008; 31(6):411-5. PubMed ID: 19096223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UCH-L1 induces podocyte hypertrophy in membranous nephropathy by protein accumulation.
    Lohmann F; Sachs M; Meyer TN; Sievert H; Lindenmeyer MT; Wiech T; Cohen CD; Balabanov S; Stahl RA; Meyer-Schwesinger C
    Biochim Biophys Acta; 2014 Jul; 1842(7):945-58. PubMed ID: 24583340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
    Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
    Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor.
    Chuang PY; Yu Q; Fang W; Uribarri J; He JC
    Kidney Int; 2007 Oct; 72(8):965-76. PubMed ID: 17667983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli.
    Xu ZG; Yoo TH; Ryu DR; Cheon Park H; Ha SK; Han DS; Adler SG; Natarajan R; Kang SW
    Kidney Int; 2005 Mar; 67(3):944-52. PubMed ID: 15698433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth arrest specific 2-like protein 1 expression is upregulated in podocytes through advanced glycation end-products.
    Liebisch M; Bondeva T; Franke S; Hause S; Wolf G
    Nephrol Dial Transplant; 2017 Apr; 32(4):641-653. PubMed ID: 27638909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D3 Partly Antagonizes Advanced-Glycation Endproducts-Induced NFκB Activation in Mouse Podocytes.
    Rüster C; Franke S; Reuter S; Mrowka R; Bondeva T; Wolf G
    Nephron; 2016; 134(2):105-116. PubMed ID: 27505422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.
    Rüster C; Bondeva T; Franke S; Tanaka N; Yamamoto H; Wolf G
    Am J Nephrol; 2009; 29(6):538-50. PubMed ID: 19129693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protective effects of erythropoietin on rat glomerular podocytes in culture are modulated by extracellular matrix proteins.
    Krtil J; Pláteník J; Čuřík N; Brima W; Tesař V; Zima T
    Kidney Blood Press Res; 2013; 38(1):142-55. PubMed ID: 24685986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms.
    Baba M; Wada J; Eguchi J; Hashimoto I; Okada T; Yasuhara A; Shikata K; Kanwar YS; Makino H
    J Am Soc Nephrol; 2005 Nov; 16(11):3222-34. PubMed ID: 16177004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo.
    Logar CM; Brinkkoetter PT; Krofft RD; Pippin JW; Shankland SJ
    Kidney Int; 2007 Aug; 72(4):489-98. PubMed ID: 17554257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.